^
Association details:
| Biomarker: | CD276 overexpression |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | vobramitamab duocarmazine (MGC018) (DNA replication inhibitor, B7-H3-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting B7-H3 in squamous cell carcinoma of the head and neck: Preclinical proof-of-concept with the investigational anti-B7-H3 antibody-drug conjugate, MGC018
Published date:
03/10/2021
Excerpt:
B7-H3 is frequently overexpressed in SCCHN. At clinically relevant dose levels, MGC018 demonstrated potent antitumor activity in vivo toward SCCHN CDX mouse models and the majority of SCCHN PDX mouse models examined.
